Haghighi Shirin, Kasbkar Hadi, Esmaeilpour Keihan, Yasaei Mehrdad
Department of Oncology, Gastroenterology and Liver Disease Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran Email :
Asian Pac J Cancer Prev. 2016;17(7):3277-80.
Gastric cancer is considered the fourth most common cancer and second most common cause of cancerrelated mortalities worldwide. Gastric cancer develops more frequently among elderly. The oxaliplatin/5FU/leucovorin (FOLFOX) regimen has shown a notable activity against gastric cancer.
To evaluate the responses and complications of FOLFOX4 regimen as first line chemotherapy in elderly patients with advanced gastric cancer.
From October 2014 to November 2015, a total of 21 patients with metastatic or local AGC (advanced gastric cancer) were analyzed. All patients were administered a FOLFOX4 regimen consisting of a 2h infusion of oxaliplatin 85 mg/m2 (day 1), continuous infusion of 1000mg/ m2 5Fu in 24h., and leucovorin 200 mg/m2 in 2h infusion as a firstline chemotherapy.
A total of 18 patients were assessable for efficacy and toxicity. One of 18 patients achieved a complete response, and 12 had partial responses, giving an overall response rate of 72.6%. Three (16%) patients demonstrated stable disease and 2 (12%) progression. The median progression free survival was 7.3 months, and the median overall survival was 11.9 months. One patient had grade 3 neuropathy. No other grade 3 or 4 NCICTC were seen.
The FOLFOX4 regimen used in our study was both active and acceptable for AGC in elderly patients as neoadjuvant and main therapy.
胃癌被认为是全球第四大常见癌症，也是癌症相关死亡的第二大常见原因。胃癌在老年人中更为常见。奥沙利铂/5-氟尿嘧啶/亚叶酸钙（FOLFOX）方案已显示出对胃癌有显著疗效。
评估FOLFOX4方案作为老年晚期胃癌患者一线化疗的疗效和并发症。
2014年10月至2015年11月，共分析了21例转移性或局部晚期胃癌（AGC）患者。所有患者均接受FOLFOX4方案作为一线化疗，包括静脉滴注85mg/m²奥沙利铂2小时（第1天），24小时持续静脉滴注1000mg/m² 5-氟尿嘧啶，以及静脉滴注200mg/m²亚叶酸钙2小时。
共有18例患者可评估疗效和毒性。18例患者中有1例完全缓解，12例部分缓解，总缓解率为72.6%。3例（16%）患者病情稳定，2例（12%）进展。无进展生存期的中位数为7.3个月，总生存期的中位数为11.9个月。1例患者出现3级神经病变。未见其他3级或4级NCICTC。
我们研究中使用的FOLFOX4方案作为新辅助治疗和主要治疗方法，对老年AGC患者有效且可接受。
